Pharmacokinetics of Cetamolol in Hypertensive Patients with Normal and Compromised Renal Function

  title={Pharmacokinetics of Cetamolol in Hypertensive Patients with Normal and Compromised Renal Function},
  author={V. A. Skoutakis and S. Acchiardo and C. Carter and C. Ingebretsen and M. Klausner and D. Lee and M. Kraml},
  journal={The Journal of Clinical Pharmacology},
The efficacy, safety, and pharmacokinetic parameters of a 30‐mg oral dose of cetamolol hydrochloride (Betacor), a new synthetic cardioselective beta‐adrenoceptor antagonist, with intrinsic sympathomimetic activity, were evaluated by studying 32 hypertensive patients with normal renal function or different degrees of renal impairment. After administration of cetamolol, serial blood and urine sample collections, as well as vital sign determinations for the next 48 hours, were performed in all… Expand
Pharmacokinetics of Newer Drugs in Patients with Renal Impairment (Part I)
Recommendations for treating patients with moderate renal insufficiency, more severe renal impairment, and end-stage renal failure with a very low creatinine clearance are given, which may vary for drugs in similar classes. Expand
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup
Atenolol and sotalol were assessed as dialyzable in patients with kidney impairment, and the workgroup suggests ECTR in patients severely poisoned with these drugs when aforementioned indications are present, whereas other BAAs were considered Dialyzable, clinical data were too limited to develop recommendations. Expand
Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data
The goal of this investigation was to evaluate the performance of a novel method allowing estimation of absolute bioavailability from oral data only, which uses total and renal clearance values following oral administration from subjects with varying renal functions to estimate bioavailability. Expand


Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate
It is suggested that cetamolol reduces BP without lowering HR at rest, during periods of increased adrenergic activity such as work and dynamic exercise, both HR and BP are reduced. Expand
Radioreceptor assay for serum levels of cetamolol, a new beta-adrenoceptor antagonist.
  • M. Stern
  • Chemistry, Medicine
  • Clinical biochemistry
  • 1984
A radioreceptor assay has been developed to measure serum drug levels and has been applied to a preliminary clinical study where serumDrug levels were detectable up to 24 h after a single oral dose of 10 or 25 mg cetamolol hydrochloride. Expand
Cetamolol: a new cardioselective beta-adrenoceptor blocking agent without membrane-stabilizing activity.
It is concluded that cetamolol lacks membrane-stabilizing activity even at inordinately high doses. Expand
Dynamics of beta-adrenoceptor blockade with cetamolol.
Cetamolol is a new beta-adrenoceptor blocking agent shown in animals to have moderate beta 1-adrenoceptor selectivity and partial agonist activity. In healthy normal volunteers, beta 1-adrenoceptorExpand
Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics.
Data are presented in tabular form that provide guidelines for drug use in adult patients with renal insufficiency. The data are derived from the current medical literature. If specific informationExpand
Cetamolol: cardiovascular effects of a new cardioselective beta-adrenoceptor blocker possessing partial agonistic activity and lacking membrane-stabilizing activity.
It is concluded that cetamolol is a potent beta-blocker with a moderate degree of partial agonistic activity and cardioselectivity in in vivo experiments. Expand
Effects of chronic cetamolol on resting, ambulatory, and exercised blood pressure heart rate
  • Clin Pharmacol Ther 1986;39:664-668
  • 1986
Cetamolol: A new renoceptor blocking agent without membrane stabilizing activity
  • Can J Physiol Pharmacol
  • 1984
AI-27, 303: A new potent 3-adrenoceptor blocking agent with cardioselectivity and intrinsic sympathomimetic activity
  • Fed Proc 1982:41:1306
  • 1982